IBD ( Inflammatory Bowel Disease )

Inflammatory Bowel Disease (IBD) is a term used to describe disorders that involve chronic inflammation of the digestive tract, including Crohn's Disease and Ulcerative Colitis. Below are COVID news and research updates that specifically relate to IBD.

Covid-19 Outcomes in Autoimmune Disease Patients

Autoimmune disease is currently considered a risk factor for severe COVID-19. A research article published in Rheumatology last Fall summarized 30-day outcomes of autoimmune disease (AD) patients following hospitalization with COVID-19. AD patients diagnosed and/or hospitalized between January and June 2020 with COVID-19 were included, and their 30 day outcomes were compared to patients with at least one AD hospitalized with influenza from September 2017 through April 2018.

Read More »

Pfizer COVID-19 Vaccine Immune Responses in Axial Spondyloarthritis Patients

A Comment piece was recently published in The Lancet regarding a small study evaluating the immunogenicity of the Pfizer COVID-19 vaccine in 17 axial spondyloarthritis patients on TNF or IL-17A inhibitors. “All patients were managed according to treatment guidelines; secukinumab (150 mg) was administered every four weeks, and adalimumab (40 mg) was administered either every 2 weeks or every three weeks.”

Read More »

Antibody Responses in Vaccinated IBD Patients

A study conducted out of Cedars-Sinai found that patients with IBD (ulcerative colitis and Crohn’s disease) produced strong antibodies following COVID-19 vaccination. Patients taking medications for other chronic inflammatory disorders have been observed to produce less antibodies depending on the medication they are taking to treat their autoimmune disease.

Read More »

IBD Patients Taking Biologics Are Not More Prone to Severe COVID

SECURE-IBD is an international collaborative database monitoring COVID-19 outcomes in IBD patients. Previous reports have indicated that IBD patients on corticosteroids and mesalamine/ sulfasalazine have an increased risk of severe COVID-19, while those on TNF antagonists do not. Proceeding analysis indicated that patients on combination therapy with TNF antagonists and thiopurines also appeared to be at higher risk of severe COVID-19 outcomes; that being said, the analysis was based on a small number of reported cases. 

Read More »
Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.